Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...
13h
Hosted on MSNWe Asked Retail Traders About Eli Lilly’s Biggest Post-Q4 Risk — Most Say It’s The Weight-Loss Drug WarsShares of Eli Lilly finished Thursday 3% higher despite an earnings report that showed sales of its blockbuster GLP-1 ...
Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.
Today, we have a look at the White House's reported plans to make major cuts across federal health agencies. Also, Eli Lilly is expanding the ...
As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...
22h
Hosted on MSNNovo Nordisk plans new study for CagriSema, targets 2026 submissionCagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...
New GLP-1RA weight loss drugs like Like Ozempic and Wegovy have become extremely popular in recent months but researchers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results